Pages that link to "Q38484762"
Jump to navigation
Jump to search
The following pages link to Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). (Q38484762):
Displaying 50 items.
- A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model (Q24276422) (← links)
- Poxvirus vectors as HIV/AIDS vaccines in humans (Q26995078) (← links)
- A global approach to HIV-1 vaccine development (Q27024614) (← links)
- A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen (Q27302081) (← links)
- Developments in HIV-1 immunotherapy and therapeutic vaccination. (Q30364312) (← links)
- Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays (Q30426851) (← links)
- A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques (Q30934059) (← links)
- The influence of delivery vectors on HIV vaccine efficacy (Q34077543) (← links)
- Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. (Q34247289) (← links)
- Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens (Q34465228) (← links)
- Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine (Q34729962) (← links)
- Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways (Q34796206) (← links)
- Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway (Q35151746) (← links)
- Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines (Q35928588) (← links)
- Extent of Systemic Spread Determines CD8+ T Cell Immunodominance for Laboratory Strains, Smallpox Vaccines, and Zoonotic Isolates of Vaccinia Virus. (Q35988486) (← links)
- Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy (Q36002028) (← links)
- Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants (Q36119504) (← links)
- Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations (Q36238314) (← links)
- A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication (Q36391900) (← links)
- Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults. (Q36668517) (← links)
- Enhancing poxvirus vectors vaccine immunogenicity. (Q36978452) (← links)
- A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection (Q37004283) (← links)
- Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells (Q37218080) (← links)
- Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies (Q37512215) (← links)
- Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design (Q37615969) (← links)
- Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. (Q37643731) (← links)
- Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies (Q38092465) (← links)
- Clinical development of Modified Vaccinia virus Ankara vaccines (Q38092470) (← links)
- Clinical applications of attenuated MVA poxvirus strain. (Q38156198) (← links)
- Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. (Q38415577) (← links)
- Developments in Viral Vector-Based Vaccines (Q38582090) (← links)
- Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors (Q39338087) (← links)
- Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression. (Q40091488) (← links)
- A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles (Q40220988) (← links)
- Microneedle-mediated delivery of viral vectored vaccines (Q40596089) (← links)
- A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. (Q40919787) (← links)
- Maternal plasma and breastmilk viral loads are associated with HIV-1-specific cellular immune responses among HIV-1-exposed, uninfected infants in Kenya. (Q41478363) (← links)
- Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. (Q41731948) (← links)
- Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice. (Q42217775) (← links)
- Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study. (Q42231663) (← links)
- Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011. (Q42411962) (← links)
- Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization (Q44569389) (← links)
- Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. (Q47375908) (← links)
- SIV-Specific Antibodies are Elicited by a Recombinant Fowlpox Virus Co-expressing SIV Gag and envT (Q56556108) (← links)
- Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B (Q57009763) (← links)
- A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses (Q64252630) (← links)
- M918: A Novel Cell Penetrating Peptide for Effective Delivery of HIV-1 Nef and Hsp20-Nef Proteins into Eukaryotic Cell Lines. (Q64966698) (← links)
- Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B (Q89633807) (← links)
- The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo (Q90646281) (← links)
- CD69 Targeting Enhances Anti-vaccinia Virus Immunity (Q91967453) (← links)